NCT00384852View on ClinicalTrials.gov

A Study of rhBMP-2/CPM in Closed Fractures of the Humerus

PHASE2CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Fractures
Interventions
DRUG

rhBMP-2/CPM

Trial Locations (37)

3004

Melbourne

4029

Herston

5000

Adelaide

9002

Oulu

11220

Brooklyn

11250

D.f.

13353

Berlin

14461

Bucharest

16801

State College

20520

Turku

21659

Bucharest

28112

Monroe

31020

Chihuahua City

33756

Clearwater

33781

St. Petersburg

43606

Toledo

44280

Guadalajara

48149

Münster

49100

Angers

50098

Bucharest

64460

Monterrey

72205

Little Rock

80012

Aurora

80204

Denver

94010

Créteil

04020-060

São Paulo

08270-070

São Paulo

V6Z 1Y6

Vancouver

L157J5

Ajax

N7M 5L9

Chatham

L1G 2B9

Oshawa

M1E 4B9

Scarborough Village

N9A 1E1

Windsor

H4J 1C5

Montreal

C1A8T5

Charlottetown

NO-0407

Oslo

SE-581 85

Linköping

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00384852 - A Study of rhBMP-2/CPM in Closed Fractures of the Humerus | Biotech Hunter | Biotech Hunter